CTRI/2024/04/065493招募中1 期
A Phase I/IIa, Open Label, Dose-Escalation, First in Human (FIH) study evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in patients with relapsed advanced malignancies - NI
Aurigene Oncology Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Diagnosis of Acute myeloid leukemia (AML) according to the World Health Organization criteria. OR
- •Myelodysplastic syndrome (MDS) according to the WHO classification.
- •Provide signed and dated informed consent and agree to comply with all study related activities.
- •ECOG status of 0 or 1.
排除标准
- •Acute promyelocytic leukemia.
- •Patients eligible for intensive chemotherapy for AML.
- •Pregnant or lactating women.
研究者
相似试验
进行中（未招募）
1 期
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)Pediatric Solid tumors and primary central nervous system (CNS) tumorsMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2023-505088-35-00F. Hoffmann-La Roche AG93
进行中（未招募）
不适用
A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophyDuchenne Muscular DystrophyEUCTR2009-013762-63-NLProsensa Therapeutics B.V18
进行中（未招募）
1 期
A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophyDuchenne Muscular DystrophyEUCTR2009-013762-63-BEProsensa Therapeutics B.V24
进行中（未招募）
不适用
A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO044 in patients with Duchenne muscular dystrophy - NDDuchenne Muscular DystrophyEUCTR2009-013762-63-ITPROSENSA THERAPEUTICS BV18
进行中（未招募）
不适用
A study to assess the effect and safety of multiple subcutaneous and intravenous doses of PRO044 in patients with Duchenne DiseaseMedDRA version: 14.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2009-013762-63-SEProsensa Therapeutics B.V24